214 related articles for article (PubMed ID: 34011212)
1. A single-centre, observational, retrospective, real-life study evaluating adalimumab biosimilar ABP 501 in the treatment of plaque-type psoriasis and psoriatic arthritis in originator-naïve patients and in patients undergoing non-medical switch from originator.
Giunta A; Zangrilli A; Bavetta M; Manfreda V; Pensa C; Bianchi L
Curr Med Res Opin; 2021 Jul; 37(7):1099-1102. PubMed ID: 34011212
[TBL] [Abstract][Full Text] [Related]
2. Effectiveness of non-medical switch from adalimumab bio-originator to SB5 biosimilar and from ABP501 adalimumab biosimilar to SB5 biosimilar in patients with chronic inflammatory arthropathies: a monocentric observational study.
Scrivo R; Castellani C; Mancuso S; Sciarra G; Giardina F; Bevignani G; Ceccarelli F; Spinelli FR; Alessandri C; Di Franco M; Riccieri V; Priori R; Conti F
Clin Exp Rheumatol; 2023 Mar; 41(3):613-619. PubMed ID: 35916302
[TBL] [Abstract][Full Text] [Related]
3. A Review of the Totality of Evidence Supporting the Development of the First Adalimumab Biosimilar ABP 501.
Markus R; McBride HJ; Ramchandani M; Chow V; Liu J; Mytych D; Fanjiang G
Adv Ther; 2019 Aug; 36(8):1833-1850. PubMed ID: 31183781
[TBL] [Abstract][Full Text] [Related]
4. Comparative effectiveness of two adalimumab biosimilars in 1318 real-world patients with inflammatory rheumatic disease mandated to switch from originator adalimumab: nationwide observational study emulating a randomised clinical trial.
Nabi H; Georgiadis S; Loft AG; Hendricks O; Jensen DV; Andersen M; Chrysidis S; Colic A; Danebod K; Hussein MR; Kalisz MH; Kristensen S; Lomborg N; Manilo N; Munk HL; Pedersen JK; Raun JL; Mehnert F; Krogh NS; Hetland ML; Glintborg B
Ann Rheum Dis; 2021 Nov; 80(11):1400-1409. PubMed ID: 33926921
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and Safety Outcomes for Originator TNF Inhibitors and Biosimilars in Rheumatoid Arthritis and Psoriasis Trials: A Systematic Literature Review.
Moots RJ; Curiale C; Petersel D; Rolland C; Jones H; Mysler E
BioDrugs; 2018 Jun; 32(3):193-199. PubMed ID: 29790131
[TBL] [Abstract][Full Text] [Related]
6. Treatment with SDZ-ADL, an Adalimumab Biosimilar, in Patients with Rheumatoid Arthritis, Psoriasis, or Psoriatic Arthritis: Results of Patient-Reported Outcome Measures from Two Phase III Studies (ADMYRA and ADACCESS).
Blauvelt A; Leonardi CL; Gaylis N; Jauch-Lembach J; Balfour A; Lemke L; Hachaichi S; Brueckmann I; Festini T; Wiland P
BioDrugs; 2021 Mar; 35(2):229-238. PubMed ID: 33651341
[TBL] [Abstract][Full Text] [Related]
7. AURIEL-PsO: a randomized, double-blind phase III equivalence trial to demonstrate the clinical similarity of the proposed biosimilar MSB11022 to reference adalimumab in patients with moderate-to-severe chronic plaque-type psoriasis.
Hercogová J; Papp KA; Chyrok V; Ullmann M; Vlachos P; Edwards CJ
Br J Dermatol; 2020 Feb; 182(2):316-326. PubMed ID: 31206593
[TBL] [Abstract][Full Text] [Related]
8. Outcomes Following a Mandatory Nonmedical Switch From Adalimumab Originator to Adalimumab Biosimilars in Patients With Psoriasis.
Loft N; Egeberg A; Rasmussen MK; Bryld LE; Nissen CV; Dam TN; Ajgeiy KK; Iversen L; Skov L
JAMA Dermatol; 2021 Jun; 157(6):676-683. PubMed ID: 33825804
[TBL] [Abstract][Full Text] [Related]
9. Switching From Originator Adalimumab to the Biosimilar SB5 in Patients With Inflammatory Bowel Disease: Short-term Experience From a Single Tertiary Clinical Centre.
Lukas M; Malickova K; Kolar M; Bortlik M; Vasatko M; Machkova N; Hruba V; Duricova D; Lukas M
J Crohns Colitis; 2020 Jul; 14(7):915-919. PubMed ID: 31905382
[TBL] [Abstract][Full Text] [Related]
10. Adalimumab and ABP 501 in the Treatment of a Large Cohort of Patients with Inflammatory Arthritis: A Real Life Retrospective Analysis.
Becciolini A; Parisi S; Caccavale R; Bravi E; Lumetti F; Andracco R; Volpe A; Gardelli L; Girelli F; Di Donato E; Santilli D; Lucchini G; Ditto MC; Platè I; Arrigoni E; Mozzani F; Riva M; Marchetta A; Fusaro E; Sandri G; Salvarani C; Paroli M; Ariani A
J Pers Med; 2022 Feb; 12(3):. PubMed ID: 35330335
[TBL] [Abstract][Full Text] [Related]
11. Cost per responder of Adalimumab biosimilars MSB11022 and ABP 501 versus the originator and methotrexate in chronic plaque psoriasis.
Gisondi P; Geat D; Armeni P; Bellinato F; Maurelli M; Girolomoni G
Expert Opin Biol Ther; 2022 Dec; 22(12):1579-1584. PubMed ID: 35466843
[TBL] [Abstract][Full Text] [Related]
12. Clinical similarity of biosimilar ABP 501 to adalimumab in the treatment of patients with moderate to severe plaque psoriasis: A randomized, double-blind, multicenter, phase III study.
Papp K; Bachelez H; Costanzo A; Foley P; Gooderham M; Kaur P; Narbutt J; Philipp S; Spelman L; Weglowska J; Zhang N; Strober B
J Am Acad Dermatol; 2017 Jun; 76(6):1093-1102. PubMed ID: 28291552
[TBL] [Abstract][Full Text] [Related]
13. Efficacy, Safety and Immunogenicity of AVT02 Versus Originator Adalimumab in Subjects with Moderate to Severe Chronic Plaque Psoriasis: A Multicentre, Double-Blind, Randomised, Parallel Group, Active Control, Phase III Study.
Feldman SR; Reznichenko N; Pulka G; Kingo K; George Galdava ; Berti F; Sobierska J; Dias R; Guenzi E; Hendrik Otto ; Haliduola HN; Kay R; Stroissnig H
BioDrugs; 2021 Nov; 35(6):735-748. PubMed ID: 34657274
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and safety of switching from reference adalimumab to SB5 in a real-life cohort of inflammatory rheumatic joint diseases.
Bruni C; Bitti R; Nacci F; Cometi L; Tofani L; Bartoli F; Fiori G; Matucci-Cerinic M
Clin Rheumatol; 2021 Jan; 40(1):85-91. PubMed ID: 32514676
[TBL] [Abstract][Full Text] [Related]
15. Uptake of tumour necrosis factor-alpha inhibitor biosimilars for psoriasis: a drug utilization study from the British Association of Dermatologists Biologic and Immunomodulators Register (BADBIR).
Phan DB; Bewley AP; Smith CH; Mackenzie T; Griffiths CEM; Lunt M; Warren RB; Yiu ZZN
Br J Dermatol; 2023 Jul; 189(1):62-70. PubMed ID: 37016153
[TBL] [Abstract][Full Text] [Related]
16. Clinical similarity of the biosimilar ABP 501 compared with adalimumab after single transition: long-term results from a randomized controlled, double-blind, 52-week, phase III trial in patients with moderate-to-severe plaque psoriasis.
Papp K; Bachelez H; Costanzo A; Foley P; Gooderham M; Kaur P; Philipp S; Spelman L; Zhang N; Strober B
Br J Dermatol; 2017 Dec; 177(6):1562-1574. PubMed ID: 28755394
[TBL] [Abstract][Full Text] [Related]
17. Real-World Experience of Adalimumab Biosimilar (ABP 501) Use in Patients with Inflammatory Bowel Disease in Europe.
Jin R; Nduka C; Courmier D; Knight H; Meadows R; Piercy J; Cummings JRF; Radziszewski W
Adv Ther; 2024 Jan; 41(1):331-348. PubMed ID: 37957522
[TBL] [Abstract][Full Text] [Related]
18. SPOSAB ABP 501: A Sicilian Prospective Observational Study of Patients with Inflammatory Bowel Disease Treated with Adalimumab Biosimilar ABP 501.
Macaluso FS; Cappello M; Busacca A; Fries W; Viola A; Costantino G; Magnano A; Vinci E; Ferracane C; Privitera AC; Piccillo G; Belluardo N; Giangreco E; Romano C; Citrano M; Graziano F; Garufi S; Bertolami C; Ventimiglia M; Scrivo B; Teresi G; Renna S; Rizzuto G; Casà A; Orlando A;
J Gastroenterol Hepatol; 2021 Nov; 36(11):3041-3049. PubMed ID: 34152636
[TBL] [Abstract][Full Text] [Related]
19. Effectiveness and safety of adalimumab biosimilar in patients with inflammatory bowel disease.
Poquet-Jornet JE; Ibáñez-Sala I; Garrigues-Pelufo T; Munilla-Das A; Valdivia-Pérez A; Carrera-Hueso FJ
Farm Hosp; 2024 Apr; ():. PubMed ID: 38570210
[TBL] [Abstract][Full Text] [Related]
20. Effectiveness and safety of adalimumab biosimilar ABP 501 in Crohn's disease: an observational study.
Ribaldone DG; Caviglia GP; Pellicano R; Vernero M; Saracco GM; Morino M; Astegiano M
Rev Esp Enferm Dig; 2020 Mar; 112(3):195-200. PubMed ID: 32054272
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
